Have we overlooked the role of mifepristone for the medical management of tubal ectopic pregnancy?

Julia Oltman, Sanjana Balachander, Ben Willem J. Mol, Andrea Woolner* (Corresponding Author)

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)

Abstract

Ectopic pregnancy is a risk of both spontaneous and assisted reproduction pregnancies. The majority of ectopic pregnancies abnormally implant within a fallopian tube (extrauterine pregnancies). In haemodynamically stable women, medical or expectant treatment can be offered. Currently accepted medical treatment is using a drug called methotrexate. However, methotrexate has potential adverse effects, and a significant proportion of women will still require emergency surgery (up to 30%) to remove the ectopic pregnancy. Mifepristone (RU-486) has anti-progesterone effects and has a role in managing intrauterine pregnancy loss and termination of pregnancy. On reviewing the literature and given progesterone’s pivotal role in sustaining pregnancy, we propose that we may have overlooked the role of mifepristone in the medical management of tubal ectopic pregnancy in haemodynamically stable women.
Original languageEnglish
Pages (from-to)1445-1448
Number of pages4
JournalHuman Reproduction
Volume38
Issue number8
Early online date9 Jun 2023
DOIs
Publication statusPublished - Aug 2023

Bibliographical note

open access via the OUP Agreement
Funding
B.W.M. is supported by a NHMRC Practitioner Fellowship (GNT1176437).

Keywords

  • mifepristone
  • ectopic pregnancy
  • methotrexate
  • fallopian tubes
  • RU148

Fingerprint

Dive into the research topics of 'Have we overlooked the role of mifepristone for the medical management of tubal ectopic pregnancy?'. Together they form a unique fingerprint.

Cite this